Nasdaq
$2.07▲ 2.48%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.0MShares out 4.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 2d agoPre-market26.10.23 20:056-KKey event#●●●#●●●#●●●
BioLineRx Ltd.Bullish
BioLineRx presented preclinical data at ESMO 2026 demonstrating that its lead candidate, GLIX1, exhibits synergy with PARP inhibitors in HR-proficient ovarian cancer models. The combination treatment showed statistically significant tumor growth inhibition in both cell lines and patient-derived xenograft models. The company plans to incorporate an ovarian cancer cohort into the expansion phase of its ongoing Phase 1/2a clinical trial.…more
$2.07+2.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5Pre-market26.10.05 13:15filedEFFECTOther
BioLineRx Ltd.
BioLineRx Ltd.'s registration statement was declared effective by the SEC on October 2, 2026. This effectiveness allows the company to proceed with the issuance and sale of securities as described in the filing.…more
$2.07+2.48%vs prev closeView filingShare - 10.2After-hours26.10.03 06:00424B3Offering
BioLineRx Ltd.
Final prospectus filed (supplement format).
$2.07+2.48%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 20:05#●●●#●●●
BioLineRx Presents Synergy Data for GLIX1 and PARP Inhibitors at ESMO 2026…more
BioLineRx and Hemispherian presented data at ESMO 2026 demonstrating that GLIX1 shows synergistic effects when combined with PARP inhibitors in ovarian cancer models. While the study showed significant tumor growth inhibition in preclinical models, it remains in the early stages of development.…more
$2.07+2.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Pre-market26.10.08 20:05
●●●●●●●● ●●●●● ●●●●●●
BioLineRx will present preclinical research and Phase 1/2a clinical trial designs for its GLIX1 candidate at the Society for Neuro-Oncology Annual Meeting. These presentations are academic in nature and do not represent immediate clinical trial results or regulatory milestones.…more
$2.07+2.48%vs prev closeShareBenzinga - 9.10Pre-market26.09.10 20:11
●●●●●●●● ●●●●● ●●●●●●
BioLineRx and Hemispherian will present preclinical efficacy data for GLIX1 in glioblastoma models at the upcoming EANO 2026 meeting. This presentation highlights early-stage research progress, with further clinical development yet to be determined.…more
$2.07+2.48%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report